Follow
Franz X. Vollenweider
Title
Cited by
Cited by
Year
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
FX Vollenweider, MFI Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, ...
Neuroreport 9 (17), 3897-3902, 1998
10391998
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
FX Vollenweider, M Kometer
Nature Reviews Neuroscience 11 (9), 642, 2010
7892010
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia
D Umbricht, L Schmid, R Koller, FX Vollenweider, D Hell, DC Javitt
Archives of general psychiatry 57 (12), 1139-1147, 2000
6972000
Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers
FX Vollenweider, A Gamma, M Liechti, T Huber
Neuropsychopharmacology 19 (4), 241-251, 1998
6061998
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
E Studerus, A Gamma, FX Vollenweider
PloS one 5 (8), e12412, 2010
5992010
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
E Studerus, M Kometer, F Hasler, FX Vollenweider
Journal of psychopharmacology 25 (11), 1434-1452, 2011
5512011
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study
F Hasler, U Grimberg, MA Benz, T Huber, FX Vollenweider
Psychopharmacology 172, 145-156, 2004
5192004
Serotonin research: contributions to understanding psychoses
MA Geyer, FX Vollenweider
Trends in pharmacological sciences 29 (9), 445-453, 2008
5152008
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
FX Vollenweider, KL Leenders, C Scharfetter, P Maguire, O Stadelmann, ...
Neuropsychopharmacology 16 (5), 357-372, 1997
5051997
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission …
FX Vollenweider, KL Leenders, I Øye, D Hell, J Angst
European Neuropsychopharmacology 7 (1), 25-38, 1997
4611997
Acute effects of lysergic acid diethylamide in healthy subjects
Y Schmid, F Enzler, P Gasser, E Grouzmann, KH Preller, FX Vollenweider, ...
Biological psychiatry 78 (8), 544-553, 2015
4532015
Gender differences in the subjective effects of MDMA
ME Liechti, A Gamma, FX Vollenweider
Psychopharmacology 154, 161-168, 2001
4482001
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG)
FX Vollenweider, KL Leenders, C Scharfetter, A Antonini, P Maguire, ...
European neuropsychopharmacology 7 (1), 9-24, 1997
4311997
A systems model of altered consciousness: integrating natural and drug-induced psychoses
FX Vollenweider, MA Geyer
Brain research bulletin 56 (5), 495-507, 2001
4142001
The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation
KH Preller, M Herdener, T Pokorny, A Planzer, R Kraehenmann, ...
Current Biology 27 (3), 451-457, 2017
3782017
5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11C] raclopride
FX Vollenweider, P Vontobel, D Hell, KL Leenders
Neuropsychopharmacology 20 (5), 424-433, 1999
3571999
Prediction of psilocybin response in healthy volunteers
E Studerus, A Gamma, M Kometer, FX Vollenweider
PloS one 7 (2), e30800, 2012
3542012
Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram
ME Liechti, C Baumann, A Gamma, FX Vollenweider
Neuropsychopharmacology 22 (5), 513-521, 2000
3402000
Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations
M Kometer, A Schmidt, L Jäncke, FX Vollenweider
Journal of Neuroscience 33 (25), 10544-10551, 2013
3362013
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
FX Vollenweider, KH Preller
Nature Reviews Neuroscience 21 (11), 611-624, 2020
3172020
The system can't perform the operation now. Try again later.
Articles 1–20